Abstract
We gave perindopril (10 mg/day) for 24 weeks to 30 patients with arterial hypertension and obesity and proved its ability to effectively lower arterial pressure, exert cardio-, angio-, and nephro-protection, improve parameters of lipid, carbohydrate and purine metabolisms in these patients. Moreover perindopril in these patients diminished manifestations of insulin resistance, hyperleptinemia, and inflammation; it also exerted pronounced positive effect on anthropometric parameters and percent of fat deposits. Basing on the aggregate of clinical and pharmacodynamics effects perindopril can be considered the drug of choice for treatment of arterial hypertension at the background of obesity.
MeSH terms
-
Adipose Tissue / drug effects
-
Adipose Tissue / metabolism
-
Adult
-
Angiotensin-Converting Enzyme Inhibitors / administration & dosage
-
Angiotensin-Converting Enzyme Inhibitors / adverse effects
-
Angiotensin-Converting Enzyme Inhibitors / pharmacokinetics
-
Blood Pressure / drug effects*
-
Body Mass Index
-
Drug Monitoring / methods*
-
Enalapril* / administration & dosage
-
Enalapril* / adverse effects
-
Enalapril* / pharmacokinetics
-
Female
-
Heart Function Tests
-
Humans
-
Hypertension / complications
-
Hypertension / drug therapy*
-
Hypertension / metabolism
-
Hypertension / physiopathology
-
Insulin Resistance
-
Kidney Function Tests
-
Male
-
Metabolism / drug effects
-
Middle Aged
-
Obesity / complications
-
Obesity / drug therapy*
-
Obesity / metabolism
-
Obesity / physiopathology
-
Perindopril* / administration & dosage
-
Perindopril* / adverse effects
-
Perindopril* / pharmacokinetics
-
Protective Agents / administration & dosage
-
Protective Agents / adverse effects
-
Protective Agents / pharmacokinetics
-
Therapeutic Equivalency
-
Treatment Outcome
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Protective Agents
-
Enalapril
-
Perindopril